Search

Home > Diabetes Knowledge into Practice Podcast > Unanswered questions: Should cardioprotective agents be offered earlier? | With Prof. Stephen Bain
Podcast: Diabetes Knowledge into Practice Podcast
Episode:

Unanswered questions: Should cardioprotective agents be offered earlier? | With Prof. Stephen Bain
Category: Health
Duration: 00:13:32
Publish Date: 2021-04-27 04:00:00
Description:

Data show that GLP-1 RAs and SGLT2 inhibitors can reduce the risk of major adverse cardiovascular events (MACE) in people with type 2 diabetes with established risk factors. Given these therapies have multifactorial benefits, and that guideline advice has been shifting towards starting dual therapy earlier for many presentations, should we consider these agents for people who are not high risk? Prof. Steve Bain answers your questions

This series will feature episodes aiming to address areas with unanswered clinical questions; first up we will be speaking to Prof. Stephen Bain about offering cardioprotective agents in type 2 diabetes. Send any questions to contact@knowledgeinpractice.eu or message us on Twitter/LinkedIn.

For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn.

References:

Disclosures:

Prof. Stephen Bain declares no relevant financial relationships

Funding statement:

This independent educational activity is supported by an educational grant from Eli Lilly, Merck Sharp & Dohme Corp and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.
Total Play: 0